ELP2 and neoplasm: While free dox and SynB1-ELP-DOXO tumors were reduced by similar amounts, there is a threefold enhancement in tumor reduction between SynB1-ELP1-DOXO and non-thermally responsive control SynB1-ELP2-DOXO, indicating that our designed ELP drug carrier can be efficiently targeted to the tumor site and effectively inhibit tumor growth in the presence of externally applied, mild hyperthermia.